U.S. markets closed
  • S&P 500

    3,998.84
    -72.86 (-1.79%)
     
  • Dow 30

    33,947.10
    -482.78 (-1.40%)
     
  • Nasdaq

    11,239.94
    -221.56 (-1.93%)
     
  • Russell 2000

    1,840.22
    -52.62 (-2.78%)
     
  • Crude Oil

    77.45
    +0.52 (+0.68%)
     
  • Gold

    1,781.20
    -0.10 (-0.01%)
     
  • Silver

    22.42
    +0.01 (+0.04%)
     
  • EUR/USD

    1.0510
    +0.0012 (+0.12%)
     
  • 10-Yr Bond

    3.5990
    +0.0930 (+2.65%)
     
  • GBP/USD

    1.2209
    +0.0015 (+0.13%)
     
  • USD/JPY

    136.3510
    -0.3340 (-0.24%)
     
  • BTC-USD

    17,001.07
    -101.85 (-0.60%)
     
  • CMC Crypto 200

    401.03
    -10.19 (-2.48%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,723.37
    -97.03 (-0.35%)
     

How Many Ibere Pharmaceuticals (NYSE:IBER) Shares Do Institutions Own?

If you want to know who really controls Ibere Pharmaceuticals (NYSE:IBER), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

Ibere Pharmaceuticals is not a large company by global standards. It has a market capitalization of US$169m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Ibere Pharmaceuticals.

View our latest analysis for Ibere Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Ibere Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Ibere Pharmaceuticals. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Ibere Pharmaceuticals' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Ibere Pharmaceuticals is not owned by hedge funds. Our data shows that Pipv Capital Llc is the largest shareholder with 19% of shares outstanding. Brown Advisory Incorporated is the second largest shareholder owning 16% of common stock, and Citadel Advisors LLC holds about 4.5% of the company stock.

On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

Insider Ownership Of Ibere Pharmaceuticals

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that Ibere Pharmaceuticals insiders own under 1% of the company. It appears that the board holds about US$981k worth of stock. This compares to a market capitalization of US$169m. We generally like to see a board more invested. However it might be worth checking if those insiders have been buying.

General Public Ownership

The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 19%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Ibere Pharmaceuticals (2 are concerning) that you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.